Frequency, Location and Nature of AAV Vector Insertions in Hemophilia A Dog Model

Characterization of AAV Vector Persistence After Long-Term Follow-up in the Hemophilia A Dog ModelПодробнее

Gene Therapy for Treatment of Hemophilia: AAV Vector Gene Therapy Application to HemophiliaПодробнее

Long-term Vector Genome Outcomes and Immunogenicity of AAV FVIII Gene Transfer in Hemophilia AПодробнее

Gene Therapy in Hemophilia: An Introduction to AAV Vector Gene TransferПодробнее

AAV Integration Summary and ImplicationsПодробнее

Directed Evolution of Next-Generation AAV Vector Systems for Clinical Gene TherapyПодробнее

David Lillicrap, MD, discusses AAV gene therapy in a canine hemophilia modelПодробнее

Federico Mingozzi: Assessing and modulating immune responses to AAV vectors in humansПодробнее

Long term Expression of AAV mediated FVIII Gene Transfer and Vector Integration EventsПодробнее

FLT180a: Next Generation AAV Vector for Hemophilia BПодробнее

Synthetic AAV vectors for gene therapy of hemophilia in childrenПодробнее

Biopharma 101: Analysis of Adeno-associated Viral (AAV) Vectors (SCIEX Webinar)Подробнее

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia AПодробнее

Unlocking the power of AAV and LVV Analytics: Insights and strategies for optimizing viral vector...Подробнее

Immunogenicity of AAV Vectors and Transgenes - Roland HerzogПодробнее

AAV gene therapies for hemophilia A and BПодробнее

AAV Gene Transfer for HemophiliaПодробнее

Structural Characterization of AAV-based Gene Therapy ProductsПодробнее

AAV Vector Shedding Assay—Best Practices in Clinical Gene Therapy Method DevelopmentПодробнее